글로벌 크론병 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

크론병 시장 분석

크론병 시장은 치료 옵션의 발전과 유병률 증가에 힘입어 역동적인 성장을 경험하고 있습니다. 시장의 발전에는 질병을 보다 효과적으로 관리할 수 있는 생물학적 제제와 표적 치료법의 도입이 포함됩니다. 예를 들어, Vedolizumab 및 Ustekinumab과 같은 새로운 단일클론 항체의 승인은 특정 염증 경로를 표적으로 삼아 환자 결과를 크게 개선했습니다. 또한 파이프라인 약물과 진행 중인 임상 시험은 경구 JAK 억제제 및 개인화된 의료 전략과 같은 새로운 치료 접근 방식을 모색하고 있습니다. 시장은 또한 제약 회사와 바이오 기술 회사가 충족되지 않은 요구를 해결하기 위해 첨단 치료법에 집중하면서 연구 개발에 대한 투자가 증가하고 있습니다. 혁신에 대한 이러한 강조가 높아지고 인식이 높아지고 진단 기술이 개선됨에 따라 시장이 앞으로 나아가 환자에게 새로운 희망을 제공하고 치료 옵션을 확대할 것으로 예상됩니다.

크론병 시장 규모

글로벌 크론병 시장 규모는 2023년에 98억 5천만 달러로 평가되었으며, 2031년까지 131억 7천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 3.70%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

크론병 시장 동향

“ 개인화 의학에 대한 집중 증가”

크론병 시장은 몇 가지 주요 트렌드가 시장을 형성하면서 진화하고 있습니다. 주목할 만한 트렌드 중 하나는 개인 환자 프로필에 따라 치료 계획을 조정하는 개인화 의학에 대한 초점이 커지고 있다는 것입니다. 예를 들어, 최근 게놈 연구의 발전으로 크론병과 관련된 특정 유전자 돌연변이를 해결하는 표적 치료법이 개발되었습니다. 항-TNF제와 Janus Kinase(JAK) 억제제와 같은 생물학적 제제와 새로운 치료법은 보다 효과적이고 개인화된 치료 옵션을 제공하기 위해 개량되고 있습니다. 이러한 트렌드는 기존 치료법에 비해 효능이 더 좋고 부작용이 적은 치료법에 대한 필요성에 의해 주도됩니다. 또한 증상 추적 및 원격 진료를 위한 모바일 앱을 포함한 디지털 건강 기술의 부상으로 환자 관리 및 준수가 개선되고 있습니다. 이러한 발전은 크론병 시장에서 보다 정확하고 환자 중심적인 접근 방식으로의 전환을 반영하여 치료 결과와 전반적인 환자 치료를 개선하고 있습니다.

보고서 범위 및 크론병 시장 세분화     

Crohn’s Disease Market Definition

Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the digestive tract, which can occur anywhere from the mouth to the anus. It commonly affects the ileum (the last part of the small intestine) and the colon (the large intestine). The inflammation caused by Crohn's disease can lead to symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. The exact cause of Crohn's disease is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors. The condition is marked by periods of flare-ups and remission, and while there is no cure, treatments are available to manage symptoms and improve quality of life.

Crohn’s Disease Market Dynamics

Drivers

• Increasing Prevalence of Crohn’s Disease

The increasing prevalence of Crohn’s disease is a significant driver of market growth, reflecting a rising global incidence of this chronic inflammatory condition. According to the Crohn's & Colitis Foundation, approximately 3 million individuals in the United States alone are affected by inflammatory bowel diseases, including Crohn’s disease. Such growing patient population underscores the urgent need for effective treatment options. As the number of diagnosed cases continues to climb, driven by factors such as improved diagnostic techniques and greater disease awareness, there is a corresponding surge in demand for innovative therapies. This heightened demand is prompting pharmaceutical companies and biotech firms to accelerate the development of new treatments, further fueling market expansion and improving the overall management of Crohn’s disease.

• Increasing Application of Stem Cells

The increasing application of stem cells in treating diseases is becoming a notable driver for the Crohn's disease market. Stem cell therapy presents new possibilities for managing and potentially curing Crohn's disease by fostering tissue repair and modulating immune responses. For instance, recent studies have investigated the use of mesenchymal stem cells (MSCs) for Crohn's disease, revealing that MSCs can diminish inflammation and facilitate healing in the gastrointestinal tract. The potential of stem cell therapy to target the root causes of the disease and improve treatment outcomes is fueling both interest and investment in this field. Such growing focus on stem cell research is contributing to the market's expansion and holds promise for advancing more effective strategies for managing Crohn's disease.

Opportunities

• Increasing Development of Advanced Imaging Techniques

The development and implementation of advanced imaging techniques, such as high-resolution magnetic resonance enterography (MRE) and capsule endoscopy, are significantly improving the accuracy and early detection of Crohn’s Disease. Additionally, the integration of novel biomarkers, such as fecal calprotectin levels and genetic markers, is enhancing diagnostic precision and differentiation from other inflammatory bowel diseases. Companies that innovate and offer these advanced diagnostic tools can tap into a growing market need for more effective early detection and monitoring solutions. By improving diagnostic capabilities, these initiatives not only facilitate earlier and more accurate diagnosis but also drive demand for targeted treatments, thereby expanding market opportunities for diagnostic and therapeutic solutions in the Crohn’s disease sector.

• Growing Awareness and Advocacy

Growing awareness and advocacy for Crohn’s disease play a crucial role in enhancing disease management and fostering proactive treatment approaches. Efforts by patient advocacy groups, such as the Crohn's & Colitis Foundation, have significantly raised public awareness and educated both patients and healthcare providers about the condition. For instance, “Take Steps” walk, an initiative by the Crohn's & Colitis Foundation, which raises millions of dollars annually to support research and patient services. Such advocacy efforts not only contribute to advancements in treatment but also improve patient access to emerging therapies and resources, thereby driving overall market growth and improving outcomes for those affected by Crohn’s disease.

Restraints/Challenges

• High Cost of Treatments

The high cost of treatments is a significant challenge in the Crohn's disease market, particularly with advanced therapies such as biologics and new targeted drugs. Medications such as Adalimumab and Ustekinumab, although effective, come with substantial price tags that can be prohibitive for many patients. High costs limits accessibility, especially for those in low-income or underinsured populations, who may find it difficult to afford these essential treatments. The financial burden extends beyond individual patients to healthcare systems, which face increased costs and budget constraints. Consequently, widespread adoption of these advanced therapies can be hindered, impacting overall market growth.

• High Cost of Advanced Crohn’s Disease

The high cost of advanced Crohn’s disease poses a significant challenge in the global market, particularly for products incorporating antimicrobial properties or cutting-edge materials. These advanced dressings, designed to enhance wound healing and prevent infections, often come with a higher price tag due to the sophisticated technologies and materials involved. For instance, antimicrobial dressings that contain silver or honey can be substantially more expensive than traditional options. Such elevated cost can limit accessibility, especially in low-resource settings where healthcare budgets are constrained and insurance coverage may be insufficient. Consequently, patients in economically disadvantaged regions or those without adequate insurance may face difficulties obtaining these advanced dressings, potentially impacting their treatment outcomes and overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Crohn’s Disease Market Scope

The market is segmented on the basis of procedures, therapeutic type, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Procedures

• Colonoscopy
• Flexible Sigmoidoscopy
• Computerized Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Capsule Endoscopy
• Double-Balloon Endoscopy
• Small Bowel Imaging

Therapeutic Type

• Non-surgical
• Surgical

End User

• Hospitals and Clinics
• Research Institutes
• Diagnostic Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Others

Crohn’s Disease Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, procedures, therapeutic type, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the Crohn's Disease market due to its advanced healthcare infrastructure, robust research and development capabilities of pharmaceutical companies, and swift adoption of cutting-edge healthcare technologies. The region's high prevalence of gastrointestinal disorders is also driving industry trends and market growth.

The Asia-Pacific region is expected to experience the highest growth rate during the forecast period, driven by increased investments in healthcare infrastructure and enhanced engagement of regulatory bodies in research and development activities. This growth is further supported by the expanding healthcare needs of a rapidly growing population and the region's ongoing efforts to modernize medical facilities and services.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Crohn’s Disease Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Crohn’s Disease Market Leaders Operating in the Market Are:

• GSK plc. (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (U.S.)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Janssen Global Services, LLC (U.S.)
• UCB S.A. (Belgium)
• Ferring (Switzerland)
• Tillotts Pharma AG (Switzerland)
• 머크앤코(미국)
• 암젠 주식회사(미국)

크론병 시장의 최신 동향

• 2022년 4월, 크론병 및 대장염 재단은 Inflammatory Bowel Disease Ventures Program에 따라 Microbiotica에 자금을 지원했습니다. 이 자금은 Microbiotica가 연구를 가속화하고 크론병과 궤양성 대장염을 관리하기 위한 새로운 치료 솔루션에 기여하는 데 도움이 될 것입니다.
• 2022년 4월, Engitix는 크론병과 같은 섬유성 협착성 염증성 장 질환에 대한 혁신적인 치료법을 발견하고 개발하는 데 집중하기 위해 Takeda와의 파트너십을 확대했습니다. 이 확장된 협업은 Engitix의 조직 모델링 전문성과 Takeda의 광범위한 치료 개발 역량을 활용하여 이러한 어려운 상태를 관리하는 데 있어 충족되지 않은 요구 사항을 해결하는 것을 목표로 합니다.

SKU-36286